CELC实时信号 | 通过Getagraph.com最大化利润

购买 109175 min ago

@ $15.21

发出时间: 13 Feb 2024 @ 22:42

回报率: 4.67%

上一信号: Feb 9 - 22:30

上一信号: 出售

回报率: 3.75 %

Live Chart Being Loaded With Signals

Commentary (27 Apr 2024 @ 04:00):

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States...

Stats
今日成交量	668 444
平均成交量	227 324
市值	484.81M
EPS	$0 ( 2024-03-27 )
下一个收益日期	( $0 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-5.92
ATR14	$0.0300 (0.19%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-24	Buller Richard E	Sell	350	Common Stock
2024-04-08	Buller Richard E	Buy	19 558	Stock Option (right to buy)
2024-04-08	Buller Richard E	Buy	12 654	Stock Option (right to buy)
2024-04-08	Buller Richard E	Buy	4 555	Stock Option (right to buy)
2024-04-08	Buller Richard E	Buy	2 310	Stock Option (right to buy)

INSIDER POWER
8.95
Last 100 transactions
Buy: 4 086 807 \| Sell: 2 961 808

音量相关性

長: -0.24 (neutral)

短: -0.27 (neutral)

Signal:(60.196) Neutral

Celcuity Inc 相关性

10 最正相关
ALKT	0.868
NNBR	0.864
DDI	0.861
AVDX	0.859
SPLK	0.856
TTSH	0.856
FCBC	0.852
BFI	0.85
ESQ	0.848
ADV	0.843

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Celcuity Inc 相关性 - 货币/商品

0.04
( neutral )

-0.50
( neutral )

0.00
( neutral )

0.53
( weak )

0.91
( very strong )

0.47
( neutral )

Celcuity Inc 财务报表

Annual	2023
营收:	$0
毛利润:	$-142 772 (0.00 %)
EPS:	$-2.69

FY	2023
营收:	$0
毛利润:	$-142 772 (0.00 %)
EPS:	$-2.69

FY	2022
营收:	$0
毛利润:	$-210 918 (0.00 %)
EPS:	$-2.68

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-2.88

Financial Reports:

No articles found.

Celcuity Inc

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was founded in 2011 and is headquartered in Minneapolis, Minnesota.